Trajan joins BioMelbourne Network

Trajan joins BioMelbourne Network

January 31, 2014

Trajan Scientific and Medical (Trajan) is now a member of BioMelbourne Network. As a group of companies with headquarters in Melbourne, Trajan is looking forward to strengthening connections with local scientific organisations, business leaders and government.

Stephen Tomisich, Trajan’s Chief Executive Officer said, “We hope our membership helps us to engage with other members to support and contribute to the success of the Australian scientific industry, in particular biotechnology in Victoria.

“We are proud to be an Australian owned and operated global company, building on humble beginnings in Ringwood with SGE Analytical Science over 50 years ago, growing to develop new analytical technologies for the scientific community and society.”

Trajan’s focus is on developing and commercializing technologies that enable analytical systems to be more selective, sensitive and specific for biological, environmental or food related measurements, especially those that can lead to portability, miniaturization and affordability.

“We seek opportunities for each of our companies with their unique capabilities. Trajan is able to facilitate collaboration with one or more of our companies in Australia and around the world.” said Robert Lyon, Head of Corporate Development at Trajan.

Trajan encompasses a group of companies including SGE Analytical Science, Grale HDS and SciMed Precision with over 300 staff worldwide, and customers in over 100 countries.

SGE Analytical Science is a world leader in creating components and consumables used in scientific analysis. SGE has substantial capability in materials science, chemistry, fabrication and distribution.

SciMed Precision offers complete solutions in design and production engineering of high precision complex components for analytical and life science applications.

Grale HDS is a pathology supply partner like no other. Supplying quality products for more than 30 years, they assist laboratory managers tackle operational challenges.

“Through true customer focus and partnerships, we aim to make a positive impact on the world of analytical and medical science.” said Mr Tomisich. 

More Information
BioMelbourne Network www.biomelbourne.org




Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More